StockVS

Kenvue Inc. (KVUE) स्टॉक विश्लेषण

रक्षात्मक उपभोक्ता

Kenvue Inc.

$17.49

$-0.04 (-0.23%)

अंतिम अपडेट: 26 मई 2026

प्राइस हिस्ट्री

हाल की खबरें

तृतीय-पक्ष स्रोतों द्वारा प्रदान की गई समाचार। वित्तीय सलाह नहीं है।

विश्लेषण

कंपनी का अवलोकन

Kenvue Inc. operates as a prominent consumer health enterprise serving markets across the United States, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America through three distinct segments: Self Care, Skin Health and Beauty, and Essential Health. The firm functions within the Consumer Defensive sector and specifically within the Household & Personal Products industry, positioning it as a provider of essential goods that typically maintain demand regardless of broader economic fluctuations. With a market capitalization of $33.41B, the company demonstrates significant scale, supported by annual revenue of $15.12B and an operational workforce comprising 21,780 employees. These financial figures indicate that Kenvue holds a substantial position in the global consumer goods landscape, reflecting a mature business model capable of generating substantial cash flows while maintaining a large-scale manufacturing and distribution infrastructure.

वित्तीय स्वास्थ्य

Kenvue reported a trailing twelve-month revenue of $15.12B with a corresponding net income of $1.47B and an EBITDA of $3.24B, illustrating a substantial gap between top-line revenue and bottom-line profit that highlights the company's cost structure and operating expenses. This gap reveals that while the business generates significant gross sales, a considerable portion is consumed by cost of goods sold, research and development, marketing expenditures, and general administrative costs before arriving at the final net income figure. The company generated $1.81B in free cash flow, which indicates a robust capacity to fund capital expenditures, service debt obligations, and potentially return capital to shareholders without relying on external financing. The firm maintains a cash balance of $1.06B against total debt of $8.67B, resulting in a debt-to-equity ratio of 80.58, which suggests a leveraged balance sheet typical for capital-intensive consumer product manufacturers. However, the current ratio stands at 0.96, indicating that short-term assets are slightly lower than short-term liabilities, suggesting a need for careful management of working capital to meet immediate obligations. Management effectiveness is further evidenced by a Return on Equity of 14.4% and a Return on Assets of 6.6%, metrics that demonstrate the company's ability to generate efficient returns on shareholder capital and utilize its asset base productively.

मूल्यांकन आकलन

The valuation metrics present a trailing P/E ratio of 22.93 compared to a forward P/E of 14.38, implying that the market expects earnings to grow significantly in the future to justify the lower forward multiple relative to current earnings. The price-to-book ratio is recorded at 3.10, indicating that the market values the company at a significant premium over its net book value, reflecting intangible assets such as brand equity and patent portfolios that are not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 2.21 and an EV/EBITDA of 12.65, which suggest that investors are willing to pay a moderate multiple relative to sales and operating earnings, consistent with stable consumer defensive stocks. Regarding trading range, the stock's 52-week high is $25.17 and the 52-week low is $14.02, providing a historical context for current pricing volatility. The beta value is 0.57, which indicates that the stock price is less volatile than the broader market, exhibiting lower sensitivity to systemic economic shifts and often moving in a more stable manner during market fluctuations.

Growth & Income

Kenvue recorded a revenue growth rate of 3.2% year-over-year alongside an earnings growth rate of 11.2% year-over-year, demonstrating that earnings are expanding at a pace nearly four times faster than revenue, which typically implies improving operational leverage and margin expansion rather than pure top-line volume growth. As a dividend payer, the company offers a dividend yield of 4.8% with a payout ratio of 108.5%, which suggests that the current dividend is being funded partially by borrowing or drawing down cash reserves rather than solely from current earnings, raising considerations regarding long-term sustainability if earnings do not accelerate. The disparity between the high payout ratio and moderate earnings growth requires monitoring to ensure the dividend can be maintained without jeopardizing financial stability. Overall, the company's profile combines moderate revenue expansion with accelerated earnings growth and a high-yield dividend, presenting a specific income-oriented investment characteristic within the consumer defensive sector.

समकक्ष तुलना

Kenvue Inc. (KVUE) घरेलू और व्यक्तिगत उत्पाद उद्योग में कार्यरत है। बाजार पूंजीकरण के आधार पर इसके निकटतम समकक्षों से तुलना इस प्रकार है:

कंपनी टिकर मार्केट कैप P/E अनुपात
Kenvue Inc. KVUE $33.58B 20.8
The Procter & Gamble Company PG $336.34B 21.1
Unilever PLC UL $123.97B 19.0
Colgate-Palmolive Company CL $71.90B 34.8

घरेलू और व्यक्तिगत उत्पाद उद्योग का औसत P/E अनुपात 29.9x है। Kenvue Inc. का P/E अनुपात 20.8 है।

यह विश्लेषण AI द्वारा केवल सूचनात्मक उद्देश्यों के लिए तैयार किया गया है और यह वित्तीय सलाह नहीं है। डेटा में देरी या अशुद्धि हो सकती है। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और किसी योग्य वित्तीय सलाहकार से परामर्श लें।

Kenvue Inc. के बारे में

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

कंपनी विवरण अंग्रेजी में दिखाया गया है।

वेबसाइट देखें →

मुख्य आंकड़े

मार्केट कैप
$33.58B
P/E अनुपात
20.82
52 सप्ताह उच्च
$23.94
52 सप्ताह निम्न
$14.02
औसत वॉल्यूम
20.88M
बीटा
0.52
डिविडेंड यील्ड
4.75%

डेटा yfinance के माध्यम से Yahoo Finance द्वारा प्रदान किया गया है। दैनिक अपडेट।

कंपनी जानकारी

एक्सचेंज
NYSE
देश
United States
कर्मचारी
21,780